Activin and Inhibin

GSK-2793660 is an orally active and irreversible inhibitor of Cathepsin C ( CTSC ). GSK-2793660 can be used for the research of bronchiectasis.Appearance:SolidIC50&amp: Target:Cathepsin C (CTSC)In Vivo:GSK-2793660 is a cathepsin C (also known as

GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1) . GSK-3484862 induces DNA hypomethylation to against cancer . GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicityIn

GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1) . GSK-3484862 induces DNA hypomethylation to against cancer . GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicityIn

GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1) . GSK-3484862 induces DNA hypomethylation to against cancer . GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicityIn

GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1) . GSK-3484862 induces DNA hypomethylation to against cancer . GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicityIn

GSK-3484862 is a non-covalent inhibitor for DNA methyltransferase (Dnmt1) . GSK-3484862 induces DNA hypomethylation to against cancer . GSK-3484862 mediates dramatic demethylation in murine embryonic stem cells with minimal non-specific toxicityIn

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1 -selective inhibitor, with an IC 50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibitionIn

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1 -selective inhibitor, with an IC 50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibitionIn

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1 -selective inhibitor, with an IC 50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibitionIn

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1 -selective inhibitor, with an IC 50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibitionIn

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1 -selective inhibitor, with an IC 50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibitionIn

GSK-5498A is a selective CARC channel inhibitor ( IC 50 : 1 μM). GSK-5498A inhibits mediators release from mast cells and pro-inflammatory cytokines release from T cells. GSK-5498A can be used in the research of inflammatory disordersIn